Chinese AI-powered drug-delivery biotech building lipid-nanoparticle and nanomaterial platforms (NanoForge) for new drug formulations.
Chinese AI-powered drug-delivery biotech building lipid-nanoparticle and nanomaterial platforms (NanoForge) for new drug formulations.
In one line: A Chinese Moderna-style AI/lipid-nanoparticle drug-delivery platform.
Moat: narrow (IP / patents, data, process know-how). Proprietary AI+quantum-chemistry nanomaterial design platform, but drug-delivery pipeline still early-stage.
Headquarters: China
Size Metis TechBio (7666.HK) is a Hong Kong Materials company (Chemicals: Major Diversified) with a market value of $1.05B, the 573rd largest of 885 Hong Kong companies the cockpit tracks. Shares closed at HK$7.25 on 18 Nov 2026.
Performance Over six months the shares fell 63.8%, against -31.1% for the median peer and -14.0% for the Hong Kong market (cap-weighted) — 2nd lowest of 21 in its peer set.
Growth Revenue grew 6,987.0% over the last twelve months (peer median +2.1%); the operating margin is -367.1% (peer median 10.7%).
Valuation It trades at 45.2× enterprise value to sales against a peer median of 2.2× (most expensive of 21).
Capital Return on invested capital runs 99.4 points below its cost of capital (5.6% WACC).
Next results Next results expected around 3 Mar 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | n/a | HK$114M | HK$1.61M | HK$10.3M | HK$644,235 |
| Revenue growth | — | +6,987% | -84% | +1,502% | — |
| Gross profit | n/a | HK$75.2M | -HK$36.2M | -HK$35.3M | -HK$7.93M |
| EBITDA | n/a | -HK$381M | -HK$372M | -HK$395M | -HK$439M |
| Net income | n/a | -HK$425M | -HK$541M | -HK$643M | -HK$596M |
| Free cash flow | n/a | -HK$152M | -HK$263M | -HK$267M | -HK$228M |
| Capital expenditure | n/a | HK$20.6M | HK$3.94M | HK$62.4M | HK$67.3M |
| Total debt | n/a | HK$146M | HK$2.49B | HK$2.42B | HK$753M |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
| Company | Market cap | 6M return | Revenue growth | Op. margin | EV / Sales | Req g |
|---|---|---|---|---|---|---|
| Metis TechBio 7666.HK | $1.05B | -64% | +6,987% | -367% | 45.2× | n/a |
| Moderna MRNA | $79.6B | +309% | +13% | -116% | 31.2× | n/a |
| XtalPi 2228.HK | $2.87B | -34% | +4% | -127% | 21.3× | n/a |
| Arcturus Therapeutics ARCT | n/a | +18% | n/a | n/a | n/a | n/a |
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | 7666.HK | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | -35.2% | -11.7% | 2nd lowest of 21 |
| 6-month return | -63.8% | -31.1% | 2nd lowest of 21 |
| Distance from 52-week high | -75.8% | -46.6% | 3rd lowest of 21 |
| Revenue growth (TTM) | +6,987.0% | +2.1% | highest of 21 |
| Operating margin | -367.1% | 10.7% | lowest of 21 |
| EV / Sales | 45.2× | 2.2× | most expensive of 21 |
| ROIC minus cost of capital | -99.4 pp | -1.8 pp | lowest of 21 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | EV / Sales | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Metis TechBio 7666.HK | Hong Kong | $1.05B | -64% | +6,987% | -367% | 45.2× | n/a | n/a |
| Victrex VCT.L | United Kingdom | $1.06B | +46% | -1% | 14% | 2.8× | 16.7% | +1.9% |
| Qingdao Huicheng Environmental Technology 300779.SZ | China | $1.08B | -48% | -13% | 5% | 10.4× | n/a | n/a |
| Jubilant Ingrevia JUBLINGREA.NS | India | $1.00B | -19% | +15% | 10% | 2.0× | 28.0% | +44.9% |
| Shanghai Emperor of Cleaning Hi-Tech 603200.SS | China | $1.12B | -24% | +4% | -8% | 15.2× | n/a | n/a |
| CNSIG Inner Mongolia Chemical Industry 600328.SS | China | $1.12B | -36% | -20% | -7% | 1.7× | n/a | n/a |
| Caregen 214370.KS | South Korea | $982M | -74% | -2% | 20% | 16.8× | 36.8% | +3.8% |
| Jinan Acetate Chemical 4763.TW | Taiwan | $1.14B | -5% | -24% | 43% | 1.9× | -20.2% | +41.2% |
| Dalian Bio-Chem 603360.SS | China | $971M | -54% | 0% | 16% | 5.1× | 8.5% | +18.4% |
| Hubei Jianghan New Materials 603281.SS | China | $1.15B | -38% | +8% | 17% | 2.4× | 3.9% | +6.3% |
| Raghav Productivity Enhancers RPEL.NS | India | $942M | +109% | +38% | 28% | 27.9× | n/a | n/a |
| Lanxess LXS.DE | Germany | $1.19B | -24% | -4% | 0% | 0.6× | 5.3% | -1.5% |
| Jilin Chemical Fibre Stock 000420.SZ | China | $1.20B | -34% | +11% | 5% | 2.6× | n/a | n/a |
| Jiangsu Zhengdan Chemical Industry 300641.SZ | China | $914M | -29% | -30% | 17% | 2.2× | 7.1% | +11.6% |
| Zhejiang Huangma Technology 603181.SS | China | $891M | -33% | +7% | 17% | 2.3× | n/a | n/a |
| Jiangsu Shuangxing Color Plastic New Materials 002585.SZ | China | $1.27B | -10% | -4% | -4% | 2.0× | 21.0% | +0.2% |
| Nippon Soda 4041.T | Japan | $1.29B | +11% | 0% | 10% | 1.5× | 5.2% | +1.8% |
| China Resources Chemical Innovative Materials 301090.SZ | China | $1.30B | -33% | +4% | 1% | 0.5× | 20.6% | +1.1% |
| Guangzhou Sanfu Newmaterials Technology 688359.SS | China | $832M | -54% | +8% | -7% | 10.2× | n/a | n/a |
| Rianlon 300596.SZ | China | $1.35B | -15% | +11% | 11% | 1.8× | n/a | n/a |
| Hanchem 014680.KS | South Korea | $1.35B | -49% | +11% | 17% | 2.1× | 5.8% | +7.4% |